Aidan Long
Overview
Explore the profile of Aidan Long including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
213
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sanders S, Fu X, Zhang Y, Perugino C, Wallwork R, Della-Torre E, et al.
Arthritis Care Res (Hoboken)
. 2020 Dec;
74(7):1188-1195.
PMID: 33342079
Objective: The etiology of IgG4-related disease (IgG4-RD) is unknown, and there has been controversy over the significance of allergic conditions in IgG4-RD. We examined the prevalence of lifetime allergy symptoms...
2.
Phadke N, Wolfson A, Mancini C, Fu X, Goldstein S, Ngo J, et al.
J Allergy Clin Immunol Pract
. 2019 Jun;
7(8):2594-2602.
PMID: 31170540
Background: Allergic condition management more often requires allergist guidance than allergy testing; necessary testing may be unavailable at initial drug allergy consultations. Electronic consultations (e-consults) provide expedited, problem-focused, potentially cost-saving...
3.
Musuku J, Engel M, Musonda P, Lungu J, Machila E, Schwaninger S, et al.
BMC Cardiovasc Disord
. 2018 Jul;
18(1):135.
PMID: 29969998
Background: The large global burden of rheumatic heart disease (RHD) has come to light in recent years following robust epidemiologic studies. As an operational research component of a broad program...
4.
Wong J, Long A
J Allergy Clin Immunol Pract
. 2017 Nov;
5(6):1564-1571.
PMID: 29122155
Background: Rituximab (Rituxan) hypersensitivity (RITS) can be severe and limits the ability to further administer the treatment. Understanding its pattern and desensitization may permit administration in difficult cases. Objective: Analyze...
5.
Long A, Lungu J, Machila E, Schwaninger S, Spector J, Tadmor B, et al.
Cardiovasc J Afr
. 2017 Sep;
28(4):242-247.
PMID: 28906539
Rheumatic heart disease is highly prevalent and associated with substantial morbidity and mortality in many resource-poor areas of the world, including sub-Saharan Africa. Primary and secondary prophylaxis with penicillin has...
6.
Lax T, Dizon D, Birrer M, Long A, Del Carmen M, Goodman A, et al.
J Allergy Clin Immunol Pract
. 2016 Sep;
5(1):177-178.
PMID: 27641482
No abstract available.
7.
Kuhlen Jr J, Camargo Jr C, Balekian D, Blumenthal K, Guyer A, Morris T, et al.
J Allergy Clin Immunol Pract
. 2016 Apr;
4(4):697-704.
PMID: 27039234
Background: Hypersensitivity reactions (HSRs) during the perioperative period are unpredictable and can be life threatening. Prospective studies for the evaluation of perioperative HSRs are lacking, and data on causative agents...
8.
Lax T, Long A, Banerji A
J Allergy Clin Immunol Pract
. 2015 Oct;
3(6):856-62.
PMID: 26432514
Carboplatin-induced hypersensitivity reactions (HSRs) are a frequent occurrence in patients being retreated for malignancy. The most common and severe reactions are thought to be IgE mediated. Currently, skin testing is...
9.
Long A, Rothman K, Chen H, Carrigan G, Szefler S
J Allergy Clin Immunol
. 2014 Dec;
135(1):289-90.
PMID: 25441293
No abstract available.
10.
Long A, Rahmaoui A, Rothman K, Guinan E, Eisner M, Bradley M, et al.
J Allergy Clin Immunol
. 2014 Apr;
134(3):560-567.e4.
PMID: 24679845
Background: The Epidemiologic Study of Xolair (omalizumab): Evaluating Clinical Effectiveness and Long-term Safety in Patients with Moderate-to-Severe Asthma (EXCELS) assessed the long-term safety of omalizumab in a clinical practice setting...